Avenue Therapeutics, Inc.
OTC: ATXI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexandra MacLean
- Employees
- 2
- Headquarters
- New York City, United States
- IPO year
- 2017
- Market cap
- $1.2M
- Website
- https://www.avenuetx.com
Loading ATXI…
Loading profile data…Frequently asked questions about ATXI
What does Avenue Therapeutics, Inc. (ATXI) do?
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently u...
Where does ATXI trade?
Avenue Therapeutics, Inc. (ATXI) trades on the Other OTC.
What sector is ATXI in?
Avenue Therapeutics, Inc. (ATXI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Avenue Therapeutics, Inc.?
Alexandra MacLean is the chief executive officer of Avenue Therapeutics, Inc. (ATXI).
Where is Avenue Therapeutics, Inc. headquartered?
Avenue Therapeutics, Inc. is headquartered in United States.
Does ATXI pay a dividend?
Avenue Therapeutics, Inc. (ATXI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATXI go public?
Avenue Therapeutics, Inc. (ATXI) completed its initial public offering in 2017.